SION-719 Fails Phase 2a Endpoint; Price Target Cut to $15.33
SION is trading near its 52-week low of $3.19 (13% above the low) on light trading volume (0.4× avg).
Summary
Sionna said SION-719 missed its key Phase 2a endpoint and will not advance, killing one of its clinical programs. The company is shifting to a Phase 2 trial of SION-451 plus galicaftor in the first quarter of 2027. Cash of $249.8M, reported with the Q3 filing on November 10, funds operations into the second half of 2029, so the failure is a pipeline setback rather than a near-term financing crisis. The average 12-month price target dropped to $15.33 from $21.57, with a wide $5 to $63 range, and consensus sits at Hold with one Buy and 10 Holds. This follows the September restructuring that cut 46% of the workforce and narrowed the pipeline to SION-451 and SION-2222. The Q1 2027 Phase 2 start is the next hard checkpoint for the remaining programs.
At the time of this announcement, SION was trading at $3.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $150.6M. The 52-week trading range was $3.19 to $54.97. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.